US FDA seeks ways to improve accelerated approvals, as drug makers explain delays
This article was originally published in SRA
The US Food and Drug Administration is holding a meeting on 8 February to review the reasons why five drug makers have failed to fulfil post-marketing confirmatory study commitments on time for drugs for which they received accelerated approval and to see whether it can provide advice about how to improve the efficiency of the expedited programme for cancer drugs1.
You may also be interested in...
Authors propose imposing penalties on drugmakers who don't start confirmatory trials shortly after accelerated approval and additional discounts for public payers; proposals could pick up steam among congressional democrats amid their renewed call for lower drug prices.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.